Table 3.
The risk of overall and cancer-specific mortality among bladder cancer patients in different BMI groups stratified by gender, age group, and clinical stage.
| Overall mortality | Cancer-specific mortality | ||||||
|---|---|---|---|---|---|---|---|
| Patients | Death (%) | AHR | p-value | Death (%) | AHR | p-value | |
| Overall | |||||||
| BMI < 18.5 | 571 | 330 (57.79) | 1.58 (1.41–1.78) | <0.0001 | 206 (36.08) | 1.50 (1.29–1.74) | <0.0001 |
| 18.5 ≦ BMI < 25 | 5,749 | 2,131 (37.07) | Ref. | 1,321 (22.98) | Ref. | ||
| BMI ≧ 25 | 4,032 | 1,108 (27.48) | 0.76 (0.71–0.82) | <0.0001 | 729 (18.08) | 0.82 (0.75–0.90) | <0.0001 |
| Stratified | |||||||
| Male | |||||||
| BMI < 18.5 | 326 | 203 (62.27) | 1.69 (1.45–1.96) | <0.0001 | 121 (37.12) | 1.52 (1.25–1.84) | <0.0001 |
| 18.5 ≦ BMI < 25 | 4,061 | 1,499 (36.91) | Ref. | 925 (22.78) | Ref. | ||
| BMI ≧ 25 | 3,013 | 763 (25.32) | 0.73 (0.67–0.80) | <0.0001 | 494 (16.4) | 0.79 (0.71–0.89) | <0.0001 |
| Female | |||||||
| BMI < 18.5 | 245 | 127 (51.84) | 1.48 (1.22–1.80) | <0.0001 | 85 (34.69) | 1.52 (1.19–1.93) | 0.0006 |
| 18.5 ≦ BMI < 25 | 1,688 | 632 (37.44) | Ref. | 396 (23.46) | Ref. | ||
| BMI ≧ 25 | 1,019 | 345 (33.86) | 0.84 (0.73–0.96) | 0.0100 | 235 (23.06) | 0.90 (0.76–1.06) | 0.2100 |
| 20–45 | |||||||
| BMI < 18.5 | 15 | 3 (20) | 2.13 (0.56–8.14) | 0.2683 | 3 (20) | 2.54 (0.65–9.89) | 0.1787 |
| 18.5 ≦ BMI < 25 | 139 | 27 (19.42) | Ref. | 23 (16.55) | Ref. | ||
| BMI ≧ 25 | 126 | 20 (15.87) | 1.01 (0.50–2.02) | 0.9884 | 18 (14.29) | 1.05 (0.50–2.23) | 0.8974 |
| 45–60 | |||||||
| BMI < 18.5 | 83 | 23 (27.71) | 1.23 (0.79–1.91) | 0.3600 | 18 (21.69) | 1.36 (0.82–2.25) | 0.2308 |
| 18.5 ≦ BMI < 25 | 982 | 223 (22.71) | Ref. | 159 (16.19) | Ref. | ||
| BMI ≧ 25 | 876 | 142 (16.21) | 0.70 (0.56–0.87) | 0.0011 | 106 (12.1) | 1.04 (0.76–1.43) | 0.7897 |
| ≧60 | |||||||
| BMI < 18.5 | 473 | 304 (64.27) | 1.65 (1.45–1.86) | <0.0001 | 185 (39.11) | 1.53 (1.30–1.79) | <0.0001 |
| 18.5 ≦ BMI < 25 | 4,628 | 1881 (40.64) | Ref. | 1,139 (24.61) | Ref. | ||
| BMI ≧ 25 | 3,030 | 946 (31.22) | 0.76 (0.70–0.83) | <0.0001 | 605 (19.97) | 0.83 (0.75–0.91) | 0.0002 |
| Stage I | |||||||
| BMI < 18.5 | 212 | 87 (41.04) | 2.15 (1.72–2.70) | <0.0001 | 39 (18.4) | 2.48 (1.76–3.49) | <0.0001 |
| 18.5 ≦ BMI < 25 | 2,893 | 652 (22.54) | Ref. | 243 (8.4) | Ref. | ||
| BMI ≧ 25 | 2,162 | 350 (16.19) | 0.69 (0.61–0.79) | <0.0001 | 168 (7.77) | 0.92 (0.75–1.12) | 0.4104 |
| Stage II | |||||||
| BMI < 18.5 | 161 | 90 (55.9) | 1.74 (1.39–2.18) | <0.0001 | 57 (35.4) | 1.64 (1.24–2.18) | 0.0006 |
| 18.5 ≦ BMI < 25 | 1,418 | 562 (39.63) | Ref. | 377 (26.59) | Ref. | ||
| BMI ≧ 25 | 1,038 | 318 (30.64) | 0.78 (0.68–0.89) | 0.0004 | 221 (21.29) | 0.80 (0.67–0.95) | 0.0091 |
| Stage III | |||||||
| BMI < 18.5 | 93 | 62 (66.67) | 1.67 (1.27–2.19) | 0.0003 | 43 (46.24) | 1.56 (1.12–2.16) | 0.0081 |
| 18.5 ≦ BMI < 25 | 763 | 383 (50.2) | Ref. | 284 (37.22) | Ref. | ||
| BMI ≧ 25 | 446 | 176 (39.46) | 0.73 (0.61–0.88) | 0.0008 | 130 (29.15) | 0.72 (0.58–0.89) | 0.0028 |
| Stage IV | |||||||
| BMI < 18.5 | 105 | 91 (86.67) | 1.15 (0.91–1.45) | 0.2432 | 67 (63.81) | 1.10 (0.84–1.43) | 0.4989 |
| 18.5 ≦ BMI < 25 | 675 | 534 (79.11) | Ref. | 417 (61.78) | Ref. | ||
| BMI ≧ 25 | 386 | 264 (68.39) | 0.84 (0.72–0.98) | 0.0240 | 210 (54.4) | 0.84 (0.71–1.00) | 0.0507 |
| NMIBC | |||||||
| BMI < 18.5 | 212 | 87 (41.04) | 2.15 (1.72–2.70) | <0.0001 | 39 (18.4) | 2.48 (1.76–3.49) | <0.0001 |
| 18.5 ≦ BMI < 25 | 2,893 | 652 (22.54) | Ref. | 243 (8.4) | Ref. | ||
| BMI ≧ 25 | 2,162 | 350 (16.19) | 0.69 (0.61–0.79) | <0.0001 | 168 (7.77) | 0.92 (0.75–1.12) | 0.4104 |
| MIBC | |||||||
| BMI < 18.5 | 359 | 243 (67.69) | 1.53 (1.34–1.76) | <0.0001 | 167 (46.52) | 1.45 (1.22–1.70) | <0.0001 |
| 18.5 ≦ BMI < 25 | 2,856 | 1,479 (51.79) | Ref. | 1,078 (37.75) | Ref. | ||
| BMI ≧ 25 | 1870 | 758 (40.53) | 0.77 (0.70–0.84) | <0.0001 | 561 (30) | 0.78 (0.70–0.86) | <0.0001 |